US FDA authorises BioCryst's IV peramivir for emergency H1N1 use – updated
This article was originally published in Scrip
The US FDA has authorised BioCryst Pharmaceuticals' antiviral IV peramivir for emergency use in hospitalised H1N1 patients. BioCryst shares were up 11% on Nasdaq in pre-market trading on October 26th on the news.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.